Debjit Chattopadhyay
Stock Analyst at Guggenheim
(3.57)
# 826
Out of 4,944 analysts
95
Total ratings
56.98%
Success rate
3.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Buy | $97 → $106 | $83.36 | +27.16% | 4 | Aug 7, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $101 → $106 | $56.86 | +86.42% | 4 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $558 → $546 | $387.77 | +40.81% | 8 | Aug 6, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Buy | $64 | $28.11 | +127.68% | 3 | Jun 20, 2025 | |
| DYN Dyne Therapeutics | Reiterates: Buy | $50 | $11.64 | +329.74% | 5 | Jun 18, 2025 | |
| QURE uniQure | Reiterates: Buy | $28 | $14.30 | +95.80% | 6 | May 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $55 → $45 | $10.86 | +314.36% | 2 | May 12, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $195 → $189 | $143.62 | +31.60% | 4 | May 7, 2025 | |
| BEAM Beam Therapeutics | Maintains: Buy | $78 → $55 | $16.86 | +226.22% | 3 | May 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $112 → $98 | $18.80 | +421.28% | 5 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $64 | $41.41 | +54.55% | 5 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $13.74 | +38.28% | 2 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $17.15 | +63.27% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $6.20 | - | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.46 | +420.23% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $12.38 | +37.32% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.98 | +114.90% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $56.60 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.38 | +333.79% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.39 | +548.97% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $25.00 | +20.00% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $1.03 | +2,715.53% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $220 | $5.61 | +3,821.57% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $429.93 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $2.91 | +862.20% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $8.45 | +136.69% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $31.66 | +288.56% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $13.01 | +315.07% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.12 | +5,257.14% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $35.38 | - | 3 | Jun 26, 2017 |
Soleno Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $97 → $106
Current: $83.36
Upside: +27.16%
BioMarin Pharmaceutical
Aug 6, 2025
Maintains: Buy
Price Target: $101 → $106
Current: $56.86
Upside: +86.42%
Vertex Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $558 → $546
Current: $387.77
Upside: +40.81%
Ultragenyx Pharmaceutical
Jun 20, 2025
Reiterates: Buy
Price Target: $64
Current: $28.11
Upside: +127.68%
Dyne Therapeutics
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $11.64
Upside: +329.74%
uniQure
May 12, 2025
Reiterates: Buy
Price Target: $28
Current: $14.30
Upside: +95.80%
Intellia Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $10.86
Upside: +314.36%
Krystal Biotech
May 7, 2025
Maintains: Buy
Price Target: $195 → $189
Current: $143.62
Upside: +31.60%
Beam Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $16.86
Upside: +226.22%
Sarepta Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $112 → $98
Current: $18.80
Upside: +421.28%
May 1, 2025
Maintains: Buy
Price Target: $65 → $64
Current: $41.41
Upside: +54.55%
Apr 2, 2025
Reiterates: Buy
Price Target: $19
Current: $13.74
Upside: +38.28%
Mar 26, 2025
Reiterates: Buy
Price Target: $28
Current: $17.15
Upside: +63.27%
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $6.20
Upside: -
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $3.46
Upside: +420.23%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $12.38
Upside: +37.32%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $6.98
Upside: +114.90%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $56.60
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $4.38
Upside: +333.79%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $3.39
Upside: +548.97%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $25.00
Upside: +20.00%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $1.03
Upside: +2,715.53%
Nov 11, 2022
Maintains: Buy
Price Target: $260 → $220
Current: $5.61
Upside: +3,821.57%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $429.93
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $2.91
Upside: +862.20%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $8.45
Upside: +136.69%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $31.66
Upside: +288.56%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $13.01
Upside: +315.07%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.12
Upside: +5,257.14%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $35.38
Upside: -